| Literature DB >> 31297574 |
Stefan Bittner1, Sinah Engel2, Christoph Lange3,4,5,6, Martin S Weber7,8, Aiden Haghikia9, Felix Luessi2, Thomas Korn10,11, Luisa Klotz12, Antonios Bayas13, Friedemann Paul14, Christoph Heesen15, Martin Stangel16, Brigitte Wildemann17, Florian Then Bergh18, Björn Tackenberg19, Corinna Trebst16, Clemens Warnke20, Ralf Linker21, Martin Kerschensteiner11,22, Uwe Zettl23, Hayrettin Tumani24,25, Wolfgang Brück7, Sven G Meuth12, Tanja Kümpfel22, Bernhard Hemmer10,11, Heinz Wiendl12, Ralf Gold9, Frauke Zipp2.
Abstract
After years of low incidence, a large increase of new tuberculosis (TB) cases has been reported in Germany since 2015. New immunotherapies for the treatment of multiple sclerosis (MS) are associated with a reduced immune competence and a potential increased risk for infections. Most neurologists lack specific experiences with TB infections. This article summarizes specific recommendations for the diagnostics and treatment of TB under MS immunotherapies with a focus on the situation in Germany. Due to low case numbers and little experience with the risk of TB under the new immunotherapies, the clinical competence network for MS (KKNMS) consensus recommendations have a low grade of evidence.Entities:
Keywords: Immune monitoring; Multiple sclerosis; Prevention; Treatment; Tuberculosis
Year: 2019 PMID： 31297574 DOI： 10.1007/s00115-019-0760-0
Source DB: PubMed Journal: Nervenarzt ISSN： 0028-2804 Impact factor: 1.214